Literature DB >> 21946081

Catabolic and anabolic actions of parathyroid hormone on the skeleton.

B C Silva1, A G Costa, N E Cusano, S Kousteni, J P Bilezikian.   

Abstract

PTH, an 84-amino acid peptide hormone synthesized by the parathyroid glands, is essential for the maintenance of calcium homeostasis.While in its traditional metabolic role, PTH helps to maintain the serum calcium concentration within narrow, normal limits and participates as a determinant of bone remodeling, more specific actions, described as catabolic and anabolic are also well known. Clinically, the catabolic effect of PTH is best represented by primary hyperparathyroidism (PHPT), while the osteoanabolic effect of PTH is best seen when PTH or its biological amino-terminal fragment [PTH(1-34)] is used as a therapy for osteoporosis. These dual functions of PTH are unmasked under very specific pathological (PHPT) or therapeutic conditions. At the cellular level, PTH favors bone resorption, mostly by affecting the receptor activator of nuclear factor κ-B (RANK) ligand (RANKL)-osteoprotegerin- RANK system, leading to an increase in osteoclast formation and activity. Increased bone formation due to PTH therapy is explained best by its ability to enhance osteoblastogenesis and/or osteoblast survival. The PTH-induced bone formation is mediated, in part, by a decrease in SOST/sclerostin expression in osteocytes. This review focuses on the dual anabolic and catabolic actions of PTH on bone, situations where one is enhanced over the other, and the cellular and molecular mechanisms by which these actions are mediated.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21946081      PMCID: PMC4315330          DOI: 10.3275/7925

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  106 in total

Review 1.  Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure.

Authors:  Juliet E Compston
Journal:  Bone       Date:  2006-10-12       Impact factor: 4.398

2.  Contributions of parathyroid hormone (PTH)/PTH-related peptide receptor signaling pathways to the anabolic effect of PTH on bone.

Authors:  D Yang; R Singh; P Divieti; J Guo; M L Bouxsein; F R Bringhurst
Journal:  Bone       Date:  2007-02-16       Impact factor: 4.398

3.  Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women.

Authors:  M Parisien; F Cosman; R W Mellish; M Schnitzer; J Nieves; S J Silverberg; E Shane; D Kimmel; R R Recker; J P Bilezikian
Journal:  J Bone Miner Res       Date:  1995-09       Impact factor: 6.741

4.  Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism.

Authors:  D W Dempster; R Müller; H Zhou; T Kohler; E Shane; M Parisien; S J Silverberg; J P Bilezikian
Journal:  Bone       Date:  2007-04-11       Impact factor: 4.398

5.  Involvement of dual signal transduction systems in the stimulation of osteoclast-like cell formation by parathyroid hormone and parathyroid hormone-related peptide.

Authors:  H Kaji; T Sugimoto; M Kanatani; M Fukase; K Chihara
Journal:  Biochem Biophys Res Commun       Date:  1993-07-15       Impact factor: 3.575

6.  The risk of hip fractures in patients with primary hyperparathyroidism: a population-based cohort study with a follow-up of 19 years.

Authors:  K Larsson; S Ljunghall; U B Krusemo; T Naessén; E Lindh; I Persson
Journal:  J Intern Med       Date:  1993-12       Impact factor: 8.989

Review 7.  Molecular and cellular mechanisms of the anabolic effect of intermittent PTH.

Authors:  Robert L Jilka
Journal:  Bone       Date:  2007-04-06       Impact factor: 4.398

8.  Cyclin D1 as a target for the proliferative effects of PTH and PTHrP in early osteoblastic cells.

Authors:  Nabanita S Datta; Glenda J Pettway; Chen Chen; Amy J Koh; Laurie K McCauley
Journal:  J Bone Miner Res       Date:  2007-07       Impact factor: 6.741

9.  Loss of cancellous bone mass and connectivity in ovariectomized rats can be restored by combined treatment with parathyroid hormone and estradiol.

Authors:  V Shen; D W Dempster; R Birchman; R Xu; R Lindsay
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

10.  IGF-I receptor is required for the anabolic actions of parathyroid hormone on bone.

Authors:  Yongmei Wang; Shigeki Nishida; Benjamin M Boudignon; Andrew Burghardt; Hashem Z Elalieh; Michelle M Hamilton; Sharmila Majumdar; Bernard P Halloran; Thomas L Clemens; Daniel D Bikle
Journal:  J Bone Miner Res       Date:  2007-09       Impact factor: 6.741

View more
  72 in total

Review 1.  The next step after anti-osteoporotic drug discontinuation: an up-to-date review of sequential treatment.

Authors:  Núria Guañabens; María Jesús Moro-Álvarez; Enrique Casado; Josep Blanch-Rubió; Carlos Gómez-Alonso; Guillermo Martínez Díaz-Guerra; Javier Del Pino-Montes; Carmen Valero Díaz de Lamadrid; Pilar Peris; Manuel Muñoz-Torres
Journal:  Endocrine       Date:  2019-04-08       Impact factor: 3.633

2.  Osteitis fibrosa cystica masquerading as bone neoplasm.

Authors:  Vishnu Vardhan Garla; Israh Akhtar; Sohail Salim; Angela Subauste
Journal:  BMJ Case Rep       Date:  2018-05-07

Review 3.  The rachitic tooth.

Authors:  Brian L Foster; Francisco H Nociti; Martha J Somerman
Journal:  Endocr Rev       Date:  2013-12-04       Impact factor: 19.871

Review 4.  Systematic review of oral manifestations related to hyperparathyroidism.

Authors:  Benjamin Palla; Egon Burian; Riham Fliefel; Sven Otto
Journal:  Clin Oral Investig       Date:  2017-06-14       Impact factor: 3.573

5.  Long term effects on mineral and bone metabolism by low versus standard calcium dialysate in peritoneal dialysis: a meta-analysis.

Authors:  Xue-Ying Cao; Jian-Hui Zhou; Guang-Yan Cai; Rui Ding; Li Tang; Di Wu; Ri-Bao Wei; Xiang-Mei Chen
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 6.  Clinical implications of bone marrow adiposity.

Authors:  A G Veldhuis-Vlug; C J Rosen
Journal:  J Intern Med       Date:  2018-01-15       Impact factor: 8.989

7.  Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation.

Authors:  Sutada Lotinun; Riku Kiviranta; Takuma Matsubara; Jorge A Alzate; Lynn Neff; Anja Lüth; Ilpo Koskivirta; Burkhard Kleuser; Jean Vacher; Eero Vuorio; William C Horne; Roland Baron
Journal:  J Clin Invest       Date:  2013-01-16       Impact factor: 14.808

8.  Skeletal changes after restoration of the euparathyroid state in patients with hypoparathyroidism and primary hyperparathyroidism.

Authors:  Cristiana Cipriani; Alice Abraham; Barbara C Silva; Natalie E Cusano; Mishaela R Rubin; Donald J McMahon; Chengchen Zhang; Didier Hans; Shonni J Silverberg; John P Bilezikian
Journal:  Endocrine       Date:  2016-10-18       Impact factor: 3.633

9.  The Deletion of Hdac4 in Mouse Osteoblasts Influences Both Catabolic and Anabolic Effects in Bone.

Authors:  Teruyo Nakatani; Tiffany Chen; Joshua Johnson; Jennifer J Westendorf; Nicola C Partridge
Journal:  J Bone Miner Res       Date:  2018-04-25       Impact factor: 6.741

10.  Inherited disorders of calcium and phosphate metabolism.

Authors:  Jyothsna Gattineni
Journal:  Curr Opin Pediatr       Date:  2014-04       Impact factor: 2.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.